Research Leadership

The Kidney Cancer Research Consortium brings together some of the nation’s best researchers in clinical kidney cancer trials, enabling multi-site studies at a greatly reduced cost.

The collaborative nature of the Consortium also improves trial enrollment numbers and access to underserved populations of patients. The KCRC includes some of the highest volume renal cell carcinoma clinical trial sites in the country.

Clinical Trial Leadership

The Consortium sites are led by veteran researchers with over 100 years of combined experience. KCRC investigators are nationally and internationally renowned for their work and heralded as thought leaders around the globe.  

What We Offer

KCRC researchers are leaders in clinical trial study design and kidney cancer treatment development. Collaboration between experienced researchers across multiple sites enables innovative study at a fraction of the cost of a traditional CRO.

Kidney Cancer Research Consortium - Patient Information for Clinical Trials

Information for Patients

Patients with kidney cancer may benefit from participation in clinical trials at any point in their treatment. Read on for more information and to locate enrolling trials.

Kidney Cancer Research News - Kidney Cancer Research Consortium

Research News

Kidney cancer research is a rapidly-advancing area of oncology. Read about the latest research coming from Consortium sites and others researching treatment for RCC.

The KCRC is the first and only kidney cancer focused clinical research consortium which allows for unique collaboration and partnerships across our academic institutions. The consortium has inspired and enabled collaboration and trial concepts that none of us could have been conducting ourselves.

– Dr. Eric Jonasch, KCRC Principal Investigator

The Kidney Cancer Research Consortium Members

The Consortium members have over 100 years of combined experience in kidney cancer clinical research. KCRC brings an unmatched commitment to and expertise to RCC trials.

The Latest Tweets from Consortium Investigators:

Load More